Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: Efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

Bone Marrow Transplantation

Volumn 51, Issue 3, 2016, Pages 365-371

  Robinson, S P ^a   Boumendil, A ^b   Finel, H ^b   Blaise, D ^c   Poire X ^d   Nicolas Virelizier, E ^e   Or, R ^f   Malladi, R ^g   Corby, A ^h   Fornecker, L ⁱ   Caballero, D ^j   Pohlreich, D ^k   Nagler, A ^l   Thieblemont, C ^m   Finke, J ⁿ   Bachy, E ^o   Vincent, L ^p   Schroyens, W ^q   Schouten, H ^r   Dreger, P ^s  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b Reduced Intensity Conditioning (RIC) Subcommittee   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e CENTRE LÉON BÉRARD   (France)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL CIVIL   (France)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k CHARLES UNIVERSITY   (Czech Republic)

^l SHEBA MEDICAL CENTER   (Israel)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o HOSPICES CIVILS DE LYON   (France)

^p LAPEYRONIE HOSPITAL   (France)

^q ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^r MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^s UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSED REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA; RISK ASSESSMENT; RISK FACTOR; ADOLESCENT; AGED; AUTOGRAFT; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AUTOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECURRENCE; RITUXIMAB; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84959519212     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.286     Document Type: Article

References (28)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
4. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
5. Gisselbrecht C, Schmitz N, Mounier N, Gingh Gill D, Linch D, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large b-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462-4469.
6. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stemcell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014; 32: 3490-3496.
7. Dhedin N, Giraudier S, Gaulard P, Esperou H, Ifrah N, Michalet M et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise De Greffe De Moelle. Br J Haematol 1999; 107: 154-161.
8. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
9. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131: 223-230.
10. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16: 35-45.
11. Bierman PJ, Sweetenham JW, Loberiza FR, Taghipour G, Lazarus HM, Rizzo JD et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744-3753.
12. Peniket AJ, Ruiz De Elvira MC, Taghipour G, Cordonnier C, Gluckman E, De Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003; 31: 667-678.
13. Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network. Canada. Bone Marrow Transplant 2000; 26: 859-864.
14. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the SocieteFrancaise De Greffe De Moelle et De TherapieCellulaire. Biol Blood Marrow Transplant 2010; 16: 78-85.
15. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Nonmyeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395-403.
16. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable longterm survival after reduced-intensity allogeneic transplantation for multiplerelapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426-432.
17. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, Ruiz De Elvira C et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
18. Cole SR, Hernán M.A. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 2004; 75: 45-49.
19. Nademanee A, Molina A, Dagis A, Snyder DS, O?Donnell MR, Parker P et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediateand high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1: 46-54.
20. Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant 2007; 13: 486-492.
21. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413.
22. Mournier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E et al. Highdose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012; 18: 788-793.
23. Hamadami M, Parameswaran HN, Zhang Y, Carreras J, Akpek G, Aljurf MD et al. Early failure of front-line Rituximab containing chemoimmunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell trnsplantation. Biol Blood Marrow Transplant 2014; 20: 1729-1736.
24. Sorror M, Giralt S, Sandmaier B, De Lima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4606-4613.
25. Van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant J-P et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348.
26. Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M et al. Rituximab after lymphoma-directed conditioning and allogeneic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomized phase 2 trial. Lancet Oncol 2014; 15: 757-766.
27. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53-59.
28. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D et al. Ageadjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996.